ALLMedicine™ Acromegaly Center
Research & Reviews 1,475 results
Pituitary Fleseriu M, Zhang Z et. al.
Nov 30th, 2022 - This systematic literature review investigated whether extended dosing intervals (EDIs) of pharmacological acromegaly treatments reduce patient burden and costs compared with standard dosing, while maintaining effectiveness. MEDLINE/Embase/the Coc...
Endocrine Chiloiro S, Giampietro A et. al.
Nov 30th, 2022 - Acromegaly is a rare but potentially life-threatening disease, if not promptly managed, for the systemic complications due to the GH/IGF-I hypersecretion. According to the increased population life span, the number of older acromegaly patients is ...
The Journal of Clinical Endocrinology and Metabolism; Gatto F, Feelders RA et. al.
Nov 23rd, 2022 - Cabergoline (CAB) is an off-label medical therapy for acromegaly, overshadowed by first-generation somatostatin receptor ligands, e.g. octreotide (OCT). Head-to-head comparison between OCT and CAB in inhibiting growth hormone (GH) secretion in pri...
Lancet (London, England); Sánchez-Meza E, Kubelis-López DE et. al.
Nov 21st, 2022 - Prominent skin folds of the scalp provide a superficial clue in acromegaly.|2022|Sánchez-Meza E,Kubelis-López DE,Ocampo-Candiani J,Chavez-Alvarez S,|diagnosis,
Archives of Endocrinology and Metabolism; Boguszewski CL
Nov 18th, 2022 - Can telemedicine improve adherence to medical treatment? Lessons learned from research on acromegaly conducted during COVID-19 pandemic.|2022|Boguszewski CL,|drug therapy,
Guidelines 5 results
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD; Baroni MG, Giorgino F et. al.
Feb 26th, 2016 - Hyperglycemia is a common feature associated with states of increased growth hormone secretion and glucocorticoid levels. The purpose of these guidelines is to assist clinicians and other health care providers to take evidence-based therapeutic de...
Nature Reviews. Endocrinology; Giustina A, Chanson P et. al.
Feb 26th, 2014 - In March 2013, the Acromegaly Consensus Group met to revise and update guidelines for the medical treatment of acromegaly. The meeting comprised experts skilled in the medical management of acromegaly. The group considered treatment goals covering...
Endocrine Practice : Official Journal of the American Col... Katznelson L, Atkinson JL et. al.
Aug 24th, 2011 - American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly--2011 update.|2011|Katznelson L,Atkinson JL,Cook DM,Ezzat SZ,Hamrahian AH,|diagnosis,therapy,standards,trends,...
Journal of Endocrinological Investigation; Cozzi R, Baldelli R et. al.
Jan 23rd, 2010 - AME Position Statement on clinical management of acromegaly.|2010|Cozzi R,Baldelli R,Colao A,Lasio G,Zini M,|diagnosis,economics,epidemiology,therapy,
The Journal of Clinical Endocrinology and Metabolism; Melmed S, Colao A et. al.
Feb 12th, 2009 - The Acromegaly Consensus Group reconvened in November 2007 to update guidelines for acromegaly management. The meeting participants comprised 68 pituitary specialists, including neurosurgeons and endocrinologists with extensive experience treating...
Drugs 30 results see all →
Clinicaltrials.gov 176 results
Oct 14th, 2022 - Acromegaly is a chronic disease caused by excessive secretion of growth hormone (GH) and mainly due to benign tumour localized in the pituitary gland. The disease develops insidiously, causing a gradual progression of symptoms; consequently most p...
Oct 14th, 2022 - Study Description: Insulin is the key hormone responsible for regulating the level of glucose in plasma. In several disease states (e.g., obesity, type 2 diabetes, and acromegaly), the target cells are resistant to insulin action. Insulin resistan...
Oct 14th, 2022 - This study aims to assess the one-year effectiveness and safety of LAN among patients with acromegaly in China in routine clinical practice. In addition, the study is designed to understand the real-world treatment patterns and outcomes of LAN amo...
Oct 6th, 2022 - A randomized, placebo-controlled study designed to evaluate the safety and efficacy of paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with non-pharmacologically treated acromeg...
Oct 6th, 2022 - A phase 2, open label, long-term extension study designed to evaluate the safety and efficacy of paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with acromegaly.
News 121 results
Oct 4th, 2022 - In super-agers -- people 80 and older with exceptional episodic memory -- entorhinal cortex neurons were significantly larger compared with cognitively average peers and individuals 20-30 years younger. (Journal of Neuroscience) A multimodal pain ...
Jul 15th, 2022 - Men with type 2 diabetes are at higher risk for testosterone deficiency. And in turn, hypogonadism is commonly associated with metabolic syndrome or type 2 diabetes. However, this does not imply a specific need for action, as Stephan Petersenn, MD...
May 4th, 2022 - The FDA placed a clinical hold on Vertex's investigational diabetes cell therapy VX-880, saying the company didn't have enough evidence to support a treatment dose increase. (Fierce Biotech) A study from England found that surgeons who performed f...
Mar 8th, 2022 - Dr Douglas S. Paauw A 64-year-old woman is evaluated for fever, diarrhea, and abdominal pain. She was diagnosed with Clostridioides difficile 2 months ago and completed a 10-day course of vancomycin. Her stool toxin test is positive for Clostridio...
Douglas S. Paauw, MD
Mar 3rd, 2022 - A 64-year-old woman is evaluated for fever, diarrhea, and abdominal pain. She was diagnosed with Clostridioides difficile 2 months ago and completed a 10-day course of vancomycin.